Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Servier
Servier
Taproot Health
Novo Nordisk A/S
Quadriga Biosciences, Inc.
Celgene
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)